Menu
Menu
Join us at the 2026 ASHG Annual Meeting in Montreal to explore how SOPHiA DDM™ supports genomic analysis and interpretation across rare and inherited disorders, including hereditary cancer, and pharmacogenomics.
Visit us at Booth #517 to connect with our genomics experts, experience SOPHiA DDM™ firsthand and discover how a data driven approach can help laboratories streamline complex genomic workflows and turn data into meaningful insights.
More ways to connect with us at ASHG
Join us at our CoLab
Hear about Trillium Health Partners’ approach to PMS2/PMS2CL disambiguation and see the latest data for our enhanced exome solutions.
Friday, October 23 | 10.15-10.45 | CoLab Theatre 2
Explore our poster presentation
Comprehensive detection of SNVs / Indels, CNVs and complex gene conversions across germline applications using an enhanced exome approach
Authors: Tamara Maas, Yuanlong Liu, Bita Khalili, Dmitri Ivanov, Alfredo Mari, Jian Yu, Rieke Kempfer, Zhenyu Xu
Wednesday, October 21, 2:30-4:30 EDT
Discover new data and insights from our latest work.
Plan your ASHG visit
Whether you're working on rare disorders, hereditary cancer, or pharmacogenomics, we'd love to connect and learn more about the challenges your laboratory is working to solve.
Meeting slots at ASHG fill quickly. Book time with our team before you arrive in Montreal.
See you there. 🧬
Hereditary cancer risk assessment is a rapidly advancing field, driven by the need for comprehensive variant detection, streamlined genomic workflows, and alignment with evolving guidelines. In the UK, testing is delivered through the NHS Genomic Laboratory Hub network, with each lab supporting a broad range of clinical indications under the National Genomic Test Directory. This webinar will highlight the experience of the West Midlands Genomic Laboratory in implementing a next-generation sequencing (NGS) solution for hereditary cancer. The session will detail how transitioning to the SOPHiA DDM™ Platform enabled the lab to improve turnaround, reduce hands-on time, and enhance variant detection. Featuring a practical walkthrough of the SOPHiA DDM™ analysis workflow, the presentation will guide attendees through each stage — from quality control to the identification of challenging variants — concluding with a preview of the new generation of SOPHiA DDM™ platform and a glimpse into the lab’s future plans for continued innovation.
Learning Objectives
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.